Toric implantable collamer lens offers good results

Article

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results.

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results, according to Daniel Elies from the Instut Oftalmologic Integral, Barcelona, Spain.

The TICL was implanted into 63 eyes of 36 patients with myopic compound astigmatism. The mean preoperative spherical equivalent (SE) was -10.58±3.41 D and the mean preoperative astigmatism was -3.59±1.38 D. The standard recommendations from the manufacturer regarding preoperative measurements, nomogram and implantation technique were followed.

Following implantation of the TICL, mean SE was -10.26 D (p<0.0001) and mean cylinder was -2.87 D (p<0.0001). Holladay analysis of astigmatism showed a large reduction.

At one-year follow-up, 82.5% of eyes had SE within ±0.50 D and 68.3± had an uncorrected visual acuity (UCVA) equal to or better than the preoperative best corrected visual acuity (BCVA). Approximately 60% of eyes gained at least one line of best spectacle corrected visual acuity (BSCVA). At two weeks postoperatively, four eyes had an intraocular pressure (IOP) over 21 mmHg due to steroids. Two eyes (of the same patient) developed adenoviric KCT and five eyes showed tilted IOL, one of which required repositioning.

Overall, Dr Elies concluded that the TICL offers predictable and effective refractive results.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.